Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;38(1):66-74.
doi: 10.1007/s00464-023-10508-w. Epub 2023 Oct 30.

Laparoscopic versus open approach for interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer: a matched comparative study

Manuel Durán-Martínez  1 , Gonzalo Gómez-Dueñas  1 , Lidia Rodriguez-Ortíz  1   2 , Juan Manuel Sanchez-Hidalgo  1   2 , Antonio Gordón-Suárez  1   2 , Ángela Casado-Adam  1   2 , Sebastián Rufián-Peña  1   2 , Francisca Valenzuela-Molina  1   2 , Blanca Rufián-Andujar  1   2 , María Carmen Vázquez-Borrego  2 , Antonio Romero-Ruiz  2 , Javier Briceño-Delgado  1 , Álvaro Arjona-Sánchez  3   4
Affiliations

Laparoscopic versus open approach for interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer: a matched comparative study

Manuel Durán-Martínez et al. Surg Endosc. 2024 Jan.

Erratum in

Abstract

Background: The use of the laparoscopic approach for the treatment of carcinomatosis from epithelial ovarian cancer (EOC) is controversial. The aim of this study was to compare the short-term outcomes of both laparoscopic and open approach for interval CRS+HIPEC in a matched cohort of patients with advanced EOC.

Methods: A retrospective analysis of a prospectively maintained database including 254 patients treated with interval CRS-HIPEC between January 2016 and December 2021 was performed. Patients with primary disease and limited carcinomatosis (PCI ≤ 10) were selected. A comparative analysis of patients treated by either open (O-CRS-HIPEC) or the laparoscopic (L-CRS-HIPEC) approach was conducted. Overall survival (OS), disease-free survival (DFS), and perioperative outcomes were analysed.

Results: Fifty-three patients were finally selected and enrolled into two comparable groups in this study. Of these, 14 patients were treated by interval L-CRS-HIPEC and 39 by interval O-CRS-HIPEC. The L-CRS-HIPEC group had a shorter hospital stay (5.6 ± 1.9 vs. 9.7 ± 9.8 days; p < 0.001) and a shorter time to return to systemic chemotherapy (4.3 ± 1.9 vs. 10.3 ± 16.8 weeks; p = 0.003). There were no significant differences in postoperative complications between both groups. The 2-year OS and DFS was 100% and 62% in the L-CRS-HIPEC group versus 92% and 60% in the O-CRS-HIPEC group, respectively (p = 0.96; p = 0.786).

Conclusion: This study suggests that the use of interval L-CRS-HIPEC for primary advanced EOC is associated with shorter hospital stay and return to systemic treatment while obtaining similar oncological results compared to the open approach. Further prospective research is needed to recommend this new approach for these strictly selected patients.

Keywords: Hyperthermic intraperitoneal chemotherapy; Interval cytoreductive surgery; Laparoscopy; Ovarian cancer; Peritoneal carcinomatosis; Peritonectomy.

PubMed Disclaimer

References

    1. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374(9698):1371–1382 - DOI - PubMed
    1. Paquette B, Kalbacher E, Mercier F, Lakkis Z, Doussot A, Turco C et al (2022) Cytoreductive surgery and intraperitoneal chemotherapy in advanced serous epithelial ovarian cancer: a 14-year French retrospective single-center study of 124 patients. Ann Surg Oncol 29(5):3322–3334 - DOI - PubMed
    1. Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 30(5):672–705 - DOI - PubMed
    1. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953 - DOI - PubMed
    1. Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V et al (2016) Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer 59:22–33 - DOI - PubMed

MeSH terms

LinkOut - more resources